Blood-based tumor biomarkers in lung cancer for detection and treatment

Hirva Mamdani, Shahid Ahmed, Samantha Armstrong, Tony Mok, Shadia Jalal

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor biology have made it imperative to obtain tumor samples on several different occasions through the course of patient treatment. While this approach is critical to the delivery of optimal cancer treatment, it is fraught with a number of barriers including the need for invasive procedures with associated complications, access to limited amount of tissue, logistical delays in obtaining the biopsy, high healthcare cost, and in many cases inability to obtain tissue because of technically difficult location of the tumor. Given multiple limitations of obtaining tissue samples, the use of blood-based biomarkers ("liquid biopsies") may enable earlier diagnosis of cancer, lower costs by avoiding complex invasive procedures, tailoring molecular targeted treatments, improving patient convenience, and ultimately supplement clinical oncologic decision-making. In this paper, we review various blood-based biomarkers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), tumor derived exosomes, tumor educated platelets (TEPs), and microRNA; and highlight current evidence for their use in detection and treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)648-660
Number of pages13
JournalTranslational Lung Cancer Research
Volume6
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Tumor Biomarkers
Lung Neoplasms
Neoplasms
Therapeutics
Biomarkers
Exosomes
Circulating Neoplastic Cells
Biopsy
MicroRNAs
Early Detection of Cancer
Health Care Costs
Blood Platelets
Costs and Cost Analysis
Mutation
DNA

Keywords

  • Blood-based biomarkers
  • Circulating tumor cell (CTC)
  • Circulating tumor DNA (ctDNA)
  • Liquid biopsy
  • Non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • Oncology

Cite this

Blood-based tumor biomarkers in lung cancer for detection and treatment. / Mamdani, Hirva; Ahmed, Shahid; Armstrong, Samantha; Mok, Tony; Jalal, Shadia.

In: Translational Lung Cancer Research, Vol. 6, No. 6, 01.12.2017, p. 648-660.

Research output: Contribution to journalReview article

Mamdani, Hirva ; Ahmed, Shahid ; Armstrong, Samantha ; Mok, Tony ; Jalal, Shadia. / Blood-based tumor biomarkers in lung cancer for detection and treatment. In: Translational Lung Cancer Research. 2017 ; Vol. 6, No. 6. pp. 648-660.
@article{1bdb2a1c855e4d34b2bd2aadd7b01668,
title = "Blood-based tumor biomarkers in lung cancer for detection and treatment",
abstract = "The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor biology have made it imperative to obtain tumor samples on several different occasions through the course of patient treatment. While this approach is critical to the delivery of optimal cancer treatment, it is fraught with a number of barriers including the need for invasive procedures with associated complications, access to limited amount of tissue, logistical delays in obtaining the biopsy, high healthcare cost, and in many cases inability to obtain tissue because of technically difficult location of the tumor. Given multiple limitations of obtaining tissue samples, the use of blood-based biomarkers ({"}liquid biopsies{"}) may enable earlier diagnosis of cancer, lower costs by avoiding complex invasive procedures, tailoring molecular targeted treatments, improving patient convenience, and ultimately supplement clinical oncologic decision-making. In this paper, we review various blood-based biomarkers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), tumor derived exosomes, tumor educated platelets (TEPs), and microRNA; and highlight current evidence for their use in detection and treatment of lung cancer.",
keywords = "Blood-based biomarkers, Circulating tumor cell (CTC), Circulating tumor DNA (ctDNA), Liquid biopsy, Non-small cell lung cancer (NSCLC)",
author = "Hirva Mamdani and Shahid Ahmed and Samantha Armstrong and Tony Mok and Shadia Jalal",
year = "2017",
month = "12",
day = "1",
doi = "10.21037/tlcr.2017.09.03",
language = "English (US)",
volume = "6",
pages = "648--660",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "6",

}

TY - JOUR

T1 - Blood-based tumor biomarkers in lung cancer for detection and treatment

AU - Mamdani, Hirva

AU - Ahmed, Shahid

AU - Armstrong, Samantha

AU - Mok, Tony

AU - Jalal, Shadia

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor biology have made it imperative to obtain tumor samples on several different occasions through the course of patient treatment. While this approach is critical to the delivery of optimal cancer treatment, it is fraught with a number of barriers including the need for invasive procedures with associated complications, access to limited amount of tissue, logistical delays in obtaining the biopsy, high healthcare cost, and in many cases inability to obtain tissue because of technically difficult location of the tumor. Given multiple limitations of obtaining tissue samples, the use of blood-based biomarkers ("liquid biopsies") may enable earlier diagnosis of cancer, lower costs by avoiding complex invasive procedures, tailoring molecular targeted treatments, improving patient convenience, and ultimately supplement clinical oncologic decision-making. In this paper, we review various blood-based biomarkers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), tumor derived exosomes, tumor educated platelets (TEPs), and microRNA; and highlight current evidence for their use in detection and treatment of lung cancer.

AB - The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor biology have made it imperative to obtain tumor samples on several different occasions through the course of patient treatment. While this approach is critical to the delivery of optimal cancer treatment, it is fraught with a number of barriers including the need for invasive procedures with associated complications, access to limited amount of tissue, logistical delays in obtaining the biopsy, high healthcare cost, and in many cases inability to obtain tissue because of technically difficult location of the tumor. Given multiple limitations of obtaining tissue samples, the use of blood-based biomarkers ("liquid biopsies") may enable earlier diagnosis of cancer, lower costs by avoiding complex invasive procedures, tailoring molecular targeted treatments, improving patient convenience, and ultimately supplement clinical oncologic decision-making. In this paper, we review various blood-based biomarkers including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), tumor derived exosomes, tumor educated platelets (TEPs), and microRNA; and highlight current evidence for their use in detection and treatment of lung cancer.

KW - Blood-based biomarkers

KW - Circulating tumor cell (CTC)

KW - Circulating tumor DNA (ctDNA)

KW - Liquid biopsy

KW - Non-small cell lung cancer (NSCLC)

UR - http://www.scopus.com/inward/record.url?scp=85031316401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031316401&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2017.09.03

DO - 10.21037/tlcr.2017.09.03

M3 - Review article

AN - SCOPUS:85031316401

VL - 6

SP - 648

EP - 660

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 6

ER -